WELCOME TO SR VAIDYA HOLISTIC WELLNESS RESEARCH INSTITUTE
Abstract
Erectile Dysfunction (ED) is defined as the persistent or recurrent inability to attain or maintain a penile erection sufficient for satisfactory sexual performance. It is a common, age-associated and clinically significant condition, with prevalence rising from approximately 5% in men aged 40–49 to over 20% in men aged 70 and above, and is now recognised as an important early marker of underlying cardiovascular and metabolic disease rather than a purely sexual complaint.
This paper examines ED from a holistic wellness perspective while maintaining the primacy of evidence-based diagnosis and appropriate medical care. It reviews global prevalence statistics, the physiological pathway of erection, the vascular, neurogenic, hormonal, psychogenic and drug-induced causes of ED, diagnostic evaluation, red-flag presentations and modern management.
The paper proposes the SR VAIDYA Integrative Framework for Erectile Dysfunction Wellness Education, built on early screening, verified diagnosis, cardiovascular risk assessment, individualised lifestyle support and responsible Ayurvedic integration.
Ayurvedic and Panchakarma approaches are discussed within clear safety boundaries as complementary wellness measures that must never replace or delay medical evaluation, particularly given the established link between ED and cardiovascular risk.
Keywords: Erectile Dysfunction, ED, Male Sexual Health, Cardiovascular Risk, IIEF-5, Holistic Wellness, Ayurveda, Panchakarma, Lifestyle Medicine, Integrative Health.
01 / Introduction
Introduction
Erectile Dysfunction is among the most common male sexual health concerns encountered in both urological and general medical practice, yet it remains under-reported due to stigma, embarrassment and limited awareness.
Population-based estimates suggest overall prevalence figures ranging widely from 3% to 76.5% depending on population age, definition and assessment method used, with prevalence consistently and strongly increasing with age (BJU International review, 2019).
The term “impotence” was historically used interchangeably with ED in public discourse; contemporary clinical terminology reserves “Erectile Dysfunction” as the precise diagnostic term, recognising it as a symptom with multiple possible underlying causes rather than a single disease entity.
02 / Global Statistics
Global Statistics and Age-Related Prevalence
Age is the single most consistent correlate of ED across population studies worldwide. Data from the Global Study of Sexual Attitudes and Behaviours demonstrate a clear, stepwise increase in prevalence with advancing age.
Prevalence of Erectile Dysfunction by Age Band
Values represented from the age-related figures stated in the supplied research content.
Consistent with this pattern, the Massachusetts Male Aging Study found that 52% of men aged 40 to 70 experienced some degree of ED, with almost 10% reporting complete erectile dysfunction, and projected the worldwide number of affected men to rise from 152 million in 1995 to 322 million by 2025 (MMAS; Feldman et al., 1994).
52%
Men aged 40–70 experiencing some degree of ED — MMAS
48.0%
Men aged 65–74 — 2021 U.S. national survey
52.2%
Men aged 75+ — 2021 U.S. national survey
A 2021 U.S. national survey using the validated IIEF-5 questionnaire found an overall prevalence of 24.2%, rising to 48.0% in men aged 65–74 and 52.2% in men aged 75 and above (National Survey of Sexual Wellbeing, 2021).
03 / Etiology
Etiological Classification
Precise etiological classification is clinically important because management differs considerably depending on whether the predominant cause is psychogenic, vascular, hormonal, neurogenic, drug-induced or structural. The European Association of Urology notes that most clinical cases are of mixed aetiology, even where one predominant cause is identified for treatment planning purposes.
01
Vasculogenic
Vascular causes are widely regarded as the most frequent organic contributor, commonly linked to atherosclerosis, hypertension, diabetes and hyperlipidaemia.
02
Neurogenic
Neurological factors can interfere with the nerve signals involved in achieving and maintaining an erection.
03
Hormonal
Endocrine contributors may include hormonal abnormalities such as hypogonadism.
04
Psychogenic
Psychological and relationship factors may contribute to erectile difficulties.
05
Drug-Induced
Certain medications, alcohol, smoking and recreational drug use may contribute to ED.
06
Structural
Penile trauma, pain or deformity may interfere with erectile function.
04 / Physiology
The Physiological Pathway of Erection
A normal erection depends on the coordinated interaction of neural, vascular and smooth-muscle mechanisms. Sexual stimulation, whether physical or psychogenic, triggers the release of nitric oxide within the cavernosal tissue, leading to smooth muscle relaxation, increased arterial inflow and compression of the venous outflow channels (veno-occlusion), which together produce and sustain penile rigidity.
Sexual Stimulation
↓
Nitric Oxide
↓
Smooth Muscle Relaxation
↓
Increased Arterial Inflow
↓
Veno-Occlusion
↓
Penile Rigidity
Erectile Dysfunction results when this pathway is disrupted at any single stage or, more commonly, at several stages simultaneously — which is why comprehensive, multi-domain assessment is more clinically useful than searching for one isolated cause.
05 / Diagnosis
Diagnostic Evaluation
A responsible approach to suspected ED begins with a structured history, validated symptom scoring and targeted investigation, always considering cardiovascular risk.
| Assessment | Purpose |
|---|---|
| IIEF-5 Questionnaire | Validated 5-item tool grading severity: mild, mild-moderate, moderate, severe |
| Detailed Medical & Sexual History | Onset (gradual vs sudden), situational vs generalised, morning erections, relationship context |
| Cardiovascular Risk Assessment | Blood pressure, lipid profile, blood glucose — given established shared risk factors |
| Hormonal Panel | Testosterone, Prolactin, TSH — identifies endocrine contributors, e.g. hypogonadism |
| Medication & Substance Review | Antihypertensives, antidepressants, alcohol, smoking, recreational drug use |
| Specialist Vascular / Doppler Studies | Selected cases with suspected vasculogenic cause or treatment non-response |
No single question or test should be interpreted in isolation. Because ED and cardiovascular disease share the same underlying vascular pathology, evaluation of a man presenting with new-onset ED should routinely include cardiovascular risk screening, particularly in men without previously known heart disease.
06 / Safety
Red Flag Presentations Warranting Urgent Assessment
Medical attention may be required
- Sudden-onset ED in a previously well man, particularly with chest pain, breathlessness or exertional symptoms — requires urgent cardiovascular assessment.
- ED accompanied by pelvic trauma, prolonged priapism, or penile pain or deformity.
- ED with signs of hypogonadism (reduced libido, fatigue, loss of body hair, gynaecomastia) warranting hormonal evaluation.
- New ED in a man with diabetes, hypertension or known cardiovascular disease — signals need for reassessment of overall cardiovascular risk control.
- ED associated with significant depression, relationship distress, or suicidal ideation — requires prompt mental health support alongside medical evaluation.
07 / Management
Modern Management of Erectile Dysfunction
Management is individualised according to identified aetiology, severity, comorbidities, patient preference and partner considerations.
First-Line
PDE5 Inhibitors
Phosphodiesterase type 5 inhibitors (e.g., sildenafil, tadalafil), alongside cardiovascular risk-factor optimisation and lifestyle modification.
Hormonal
Hormonal Therapy
Testosterone replacement in confirmed hypogonadism, under appropriate monitoring.
Psychological
Psychosexual Therapy
Particularly valuable in predominantly psychogenic or performance-anxiety-related ED, and often combined with pharmacotherapy.
Second-Line
Intracavernosal Injections
An option for men not responding to or unsuitable for oral therapy.
Second-Line
Vacuum Erection Devices
A non-oral treatment option for selected men.
Third-Line
Penile Prosthesis
Penile prosthesis implantation in selected cases refractory to other treatments.
08 / Cardiovascular Health
The Cardiovascular and Metabolic Connection
ED and cardiovascular disease share common underlying vascular pathology — endothelial dysfunction, atherosclerosis and impaired nitric oxide bioavailability.
Obesity
Established shared cardiovascular and metabolic risk factor.
Diabetes
Associated with a strikingly high burden of ED.
Hypertension
Established vascular risk factor associated with ED.
Dyslipidaemia
Can contribute to vascular dysfunction.
Smoking
Established modifiable risk factor.
Physical Inactivity
Associated with cardiovascular and metabolic risk.
ED Prevalence Among Men With Diabetes
Pooled global prevalence reported in the supplied 2024 umbrella review.
A holistic assessment may therefore include attention to body weight, waist circumference, blood pressure, lipid profile, blood glucose, sleep quality and physical activity, in addition to targeted sexual health history.
09 / Ayurveda
Ayurvedic and Holistic Wellness Perspective
Ayurvedic literature describes erectile difficulties under Klaibya, within the broader context of Vajikarana (rejuvenative and reproductive health science), with traditional emphasis on Shukra Dhatu (reproductive tissue) balance, Ahara (diet), Vihara (lifestyle), Nidra (sleep) and stress management.
10 / Panchakarma
Panchakarma: The Need for Responsible Integration
Panchakarma represents an important therapeutic system within Ayurveda. Its consideration in individuals with ED requires careful assessment of cardiovascular stability, diabetes status, current medications (particularly nitrates, where interaction with certain treatments is a recognised safety concern), and general health, given the physiological demands some procedures place on the body.
Within appropriately supervised settings and stable cardiovascular status, general categories such as structured Ahara-based dietary correction, stress-reduction practices and mild, individualised Basti protocols have been discussed in traditional literature as supportive measures.
Any such intervention requires practitioner-level clinical judgement, is contraindicated in unstable cardiovascular disease, uncontrolled diabetes or active infection, and must be sequenced around — never in place of — cardiovascular risk assessment and medical management.
Important Principle
Panchakarma should not be promoted as a treatment for ED arising from unstable cardiovascular disease, uncontrolled diabetes, hormonal deficiency, or as a substitute for validated pharmacological therapy.
11 / SR VAIDYA Framework
The SR VAIDYA Holistic Wellness Framework
The following integrative framework is proposed for responsible holistic wellness education in ED care, structured around the Institute's name to support ease of recall among practitioners and patients alike.
S
SCREEN
R
VERIFY
V
REFER
A
SUPPORT
I
MONITOR
D
EDUCATE
Y-A
FOLLOW UP
12 / Root-Factor Analysis
Root-Factor Analysis: A Scientifically Responsible Approach
Erectile Dysfunction does not arise from a single root cause. A more scientifically defensible concept is Root-Factor Analysis, which identifies multiple vascular, neurogenic, hormonal, psychological, lifestyle, medication-related and comorbid-disease factors contributing to an individual's overall presentation and treatment response.
Vascular
Neurogenic
Hormonal
Psychological
Lifestyle
Medication
Comorbid Disease
13 / Evidence
Evidence Grading of Key Claims
In keeping with the Institute's evidence-grading standard, the principal claims discussed in this paper are graded below as Strong, Moderate or Weak, reflecting the current weight of peer-reviewed evidence.
| Claim | Evidence Grade | Basis |
|---|---|---|
| ED prevalence increases consistently with age | Strong | Multiple large population studies (GSSAB; MMAS; NSSW 2021) |
| ED is an early marker of cardiovascular disease risk | Strong | Consistent shared-pathophysiology and longitudinal evidence |
| PDE5 inhibitors are effective first-line pharmacological therapy | Strong | Extensive randomised controlled trial evidence |
| Weight loss, exercise and smoking cessation improve erectile function as adjunctive measures | Moderate | Multiple observational and some randomised studies |
| Specific Ayurvedic herbal formulations improve IIEF scores comparably to PDE5 inhibitors | Weak | Limited, heterogeneous trials; insufficient for treatment substitution |
| Panchakarma alone reverses vasculogenic or hormonal ED | Weak / Unsupported | No robust controlled evidence; contraindicated as sole therapy |
14 / Discussion
Discussion
The future of ED care increasingly requires integration without exaggeration. Conventional medicine provides diagnostic precision, pharmacological therapy, hormonal treatment and surgical options where indicated, alongside crucial cardiovascular risk screening.
Holistic wellness can contribute through lifestyle education, stress management, sleep improvement, weight management and patient empowerment.
A successful integrative model should therefore be evidence-aware, patient-centred, safety-oriented, referral-conscious, cardiovascular-risk-aware and individualised — consistent with the approach adopted throughout this paper.
15 / Recommendations
Proposed Conference Recommendations
1
Treat new-onset ED as an opportunity for cardiovascular risk screening, not solely a sexual health complaint.
2
Train wellness practitioners to recognise red-flag presentations, especially sudden-onset ED with cardiac symptoms, requiring urgent referral.
3
Focus lifestyle interventions on modifiable vascular and metabolic risk factors rather than claiming to cure ED of all aetiologies.
4
Use validated assessment tools (IIEF-5) for diagnosis, severity grading and monitoring of treatment response.
5
Individualise Ayurvedic and Panchakarma interventions and never delay cardiovascular assessment or validated pharmacological therapy.
6
Conduct ethically designed observational and controlled studies of integrative wellness approaches in ED.
7
Study quality of life, psychological wellbeing and cardiovascular risk-factor outcomes without unsupported cure claims.
16 / Future Research
Future Research Proposal for SR VAIDYA
“Effect of a Structured Holistic Lifestyle Programme on Erectile Function and Cardiovascular Risk Markers in Men with Mild-to-Moderate Erectile Dysfunction Receiving Standard Medical Care.”
17 / Conclusion
Conclusion
Erectile Dysfunction is a common, age-associated condition with important vascular, neurogenic, hormonal and psychological dimensions, and carries significant value as an early marker of cardiovascular risk. Responsible care requires both precise medical evaluation and sustained lifestyle support.
SCREEN → VERIFY → REFER → SUPPORT → FOLLOW UP
Holistic wellness has an important role in promoting healthy lifestyle behaviours, cardiovascular health, stress management and patient awareness. However, responsible integration requires clear boundaries.
Acknowledgement
Acknowledgement
The author acknowledges the importance of interdisciplinary dialogue between conventional medicine, urology, cardiology, Ayurveda, lifestyle medicine and holistic wellness research in developing patient-centred and scientifically responsible approaches to Erectile Dysfunction.
References
References
- Kessler, A., Sollie, S., Challacombe, B., Briggs, K., & Van Hemelrijck, M. (2019). The global prevalence of erectile dysfunction: A review. BJU International, 124(4), 587–599.
- Feldman, H. A., Goldstein, I., Hatzichristou, D. G., Krane, R. J., & McKinlay, J. B. (1994). Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. Journal of Urology, 151(1), 54–61.
- Rosen, R. C., Fisher, W. A., Eardley, I., Niederberger, C., Nadel, A., & Sand, M. (2004). The Multinational Men's Attitudes to Life Events and Sexuality (MALES) study. Current Medical Research and Opinion, 20(5), 607–617.
- Herbenick, D., Fu, T. J., Patterson, C., Rosen, R. C., & Sanders, S. A. (2024). Erectile dysfunction prevalence in the United States: Report from the 2021 National Survey of Sexual Wellbeing. Journal of Sexual Medicine, 21(4), 296–303.
- Yafi, F. A., Jenkins, L., Albersen, M., Corona, G., Isidori, A. M., Goldfarb, S., Maggi, M., Nelson, C. J., Parish, S., Salonia, A., Tan, R., Mulhall, J. P., & Hellstrom, W. J. G. (2016). Erectile dysfunction. Nature Reviews Disease Primers, 2, 16003.
- Deveci, S., O'Brien, K., Ahmed, A., Parker, M., Guhring, P., & Mulhall, J. P. (2014). Comparison of the simplified International Index of Erectile Function (IIEF-5) in patients of erectile dysfunction with different pathophysiologies. BMC Urology, 14, 52.
- Defeudis, G., Mazzilli, R., Tenuta, M., Rossini, G., Zamponi, V., Olana, S., Faggiano, A., Pozzilli, P., Isidori, A. M., & Gianfrilli, D. (2024). Erectile dysfunction and diabetes: A melting pot of circumstances and treatments. Diabetes/Metabolism Research and Reviews, 40(2), e3768.